SCHEMBL2791306

SCHEMBL2791306

O=C(Oc1ccccc1)c1cc(S(=O)(=O)c2ccccc2)c2ccccc2c1O

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCL1 Q07820 12/20 0.49
HSD17B10 Q99714 2/20 0.49
CYP2C9 P11712 1/20 0.49
MAPT P10636 2/20 0.47
HPGD P15428 1/20 0.45
ALOX15 P16050 1/20 0.45
BCL2L1 Q07817 4/20 0.44
NSD2 O96028 1/20 0.43
NR4A2 P43354 1/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CYP3A4 P08684 1/20 0.43
ADORA3 P0DMS8 1/20 0.43
CHRM1 P11229 1/20 0.43
TBXA2R P21731 1/20 0.43
SLC6A2 P23975 1/20 0.43
PDE4A P27815 1/20 0.43
ADRA1A P35348 1/20 0.43
KDR P35968 1/20 0.43
SLC6A3 Q01959 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2789013 0.83 MCL1 (0.69) MCL1HSD17B10CYP2C9MAPTHPGD
SCHEMBL590944 0.78 THRB (0.64) MCL1HSD17B10CYP2C9MAPTHPGD
SCHEMBL2791312 0.76 NSD2 (0.41) HSD17B10MAPTHPGDALOX15NSD2
SCHEMBL7797719 0.76 MAPT (0.66) HSD17B10CYP2C9MAPTHPGDALOX15
SCHEMBL11066829 0.76 HPGD (0.51) MCL1HSD17B10CYP2C9MAPTHPGD
SCHEMBL10489198 0.71 ALOX5 (0.50) HSD17B10MAPTHPGDALOX15NSD2
SCHEMBL5026751 0.71 HSD17B10 (0.61) HSD17B10CYP2C9MAPTHPGDALOX15
SCHEMBL5612390 0.70 MAPT (0.58) HSD17B10MAPTHPGDALOX15NSD2
SCHEMBL29361815 0.69 LDHA (0.64) HSD17B10MAPTHPGDALOX15NSD2
SCHEMBL27607 0.69 LDHA (0.64) HSD17B10MAPTHPGDALOX15NSD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDICK A/S (DK) 2010-02-18 US disclosed
EP-1881961-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2008-01-30 EP disclosed
WO-2006120178-A1 NEW HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES NOVO NORDISK A/S (DK) 2006-11-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041657-A1 HALOALKYLSULFONE SUBSTITUTED COMPOUNDS USEFUL FOR TREATING OBESITY AND DIABETES RPS12, GPR119, ATP12A MCL1 4446/4885HSD17B10 15/4885CYP2C9 1431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.